Dizal Pharmaceutical Co., Ltd. IPO: Date, Status and What We Know
IPO facts
- Status
- Filed
- Market
- Hong Kong & China
- Country
- Hong Kong
- Exchange
- Hong Kong Stock Exchange Main Board
- Ticker
- Not announced
- Sector
- Biopharmaceuticals (oncology)
- Filing date
- First trading day
- Not announced
- Price range
- Not announced
- Offering size
- Not announced
- Last valuation
- Not announced
About Dizal Pharmaceutical Co., Ltd.
Dizal is a commercial-stage biopharmaceutical company focused on oncology and haematological diseases. It commercialised golidocitinib, a JAK1 inhibitor, in the Chinese mainland, and developed and out-licensed ZEGFROVY, an EGFR inhibitor approved for lung cancer with exon 20 insertion mutations. Its A shares are listed on the Shanghai Stock Exchange STAR Market under the code 688192.
IPO notes
Dizal Pharmaceutical Co., Ltd. posted its application proof on hkexnews.hk on 27 August 2026. The proof redacts the offer size, price range and timetable. As of 5 October 2026 the application was listed as active on hkexnews.hk, with no post-hearing information pack, offer period, price or listing date published.
Other IPOs in this market
Sources
- hkexnews.hk · Application proof (first submission) ·
- hkexnews.hk · List of active listing applications (status as of 5 October 2026) ·
Named as plain text with what each source states and the date it was checked.